Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2010-06-21
2011-10-04
Sang, Hong (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100
Reexamination Certificate
active
08029788
ABSTRACT:
The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5472693 (1995-12-01), Gourlie et al.
patent: 5482040 (1996-01-01), Martin, Jr.
patent: 5512443 (1996-04-01), Schlom et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5976531 (1999-11-01), Mezes et al.
patent: 5976845 (1999-11-01), Mezes et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6333405 (2001-12-01), Anderson et al.
patent: 6495137 (2002-12-01), Mezes et al.
patent: 7081518 (2006-07-01), Pastan et al.
patent: 2131355 (1996-03-01), None
patent: 2068593 (2003-07-01), None
patent: 0239400 (1987-09-01), None
patent: 0365997 (1990-05-01), None
patent: WO 89/00692 (1989-01-01), None
patent: WO 89/01783 (1989-03-01), None
patent: WO 90/04410 (1990-05-01), None
patent: WO 91/00295 (1991-01-01), None
patent: WO 93/12231 (1993-06-01), None
patent: WO 96/13594 (1996-05-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO 98/18809 (1998-05-01), None
patent: WO 99/43816 (1999-09-01), None
patent: WO 00/26394 (2000-05-01), None
patent: WO 2004/003155 (2004-01-01), None
patent: WO 2005/021594 (2005-03-01), None
Fundamental Immunology, William E. Paul, M.D. ed., 3rd ed., p. 242, 1993.
Rudikoff et al., Proc Natl Aced Sci USA 1982 vol. 79, 1979-1983.
Alvarez, et al., A Phase I Study of Combined Modality90Yttrium-CC49 Intraperitoneal Radioimmunotherapy for Ovarian Cancer,Clinical Cancer Research, 8:2806-2811, Sep. 2002.
Chinn, et al., “Pharmacokinetics and Tumor Localization of (111)in-Labeled HuCC49DeltaC(H)2 in BALB/c Mice and Athymic Murine Colon Carcinoma Xenograft,”Cancer Biothur Radiopharm., 21(2):106-116, Apr. 2006. Abstract Only.
Forero, et al., “A Novel Monoclonal Antibody Design for Radioimmunotherapy,”Cancer Biothur Radiopharm., 18(5):751-759, Oct. 2003. Abstract Only.
Abergel et al., “Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab',”Proteins: Structure, Function, and Genetics17:438-443, 1993.
Adams and Schier, “Generating improved single-chain Fv molecules for tumor targeting,”Journal of Immunological Methods, 231(1-2):249-260, 1999.
Bending, “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,”Methods: A Companion to Methods in Enzymology, 8:83-93 (1995).
Cameron, Ewan R., “Recent Advances in Transgenic Technology,”Molecular Biotechnology, 7(3):253-265, Jun. 1997.
Colcher et al., “Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies,”Cancer Research48:4597-4603, 1988.
De Pascalis et al., “In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants,”Clinical Cancer Research, 9(15):5521-5531 (2003).
De Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,”J. Immunol. 169:3076-3084 (2002).
Divgi et al., “Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen,”Nucl. Med. Biol. 21(1):9-15, 1994.
Gonzales et al., “Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues,”Mol. Immunol., 40:337-349, 2003.
Gonzales et al., “Reducing the potential immunogenicity of humanized CC49 by genetic manipulation of framework residues,”Proceedings of the American Association for Cancer Research, 44:1118, 2003.
Hakimi et al., “Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys,”J Immunol. 147:1352-1359, 1991.
Hammer, et al., “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLS-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders,”Cell, 63(5):1099-1112, Nov. 30, 1990.
Hand et al., “Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma,” Cancer Supplement 73(3):1105-1113, 1994.
Houdebine, Louis-Marie, “Production of Pharmaceutical Proteins from Transgenic Animals,” Journal of Biotechnology, 34(3):269-287, May 31, 1994.
Iwahashi et al., “CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity,”Molecular Immunology36:1079-1091, 1999.
Johnson et al., “Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3,”Cancer Research46:850-857, 1986.
Jones et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,”Nature321:522-525, 1986.
Kappel, et al., “Regulating Gene Expression in Transgenic Animals,”Current Opinion in Biotechnology, 3(5):548-553, Oct. 1991.
Kashmiri et al, “Generation, Characterization, and in Vivo Studies of Humanized Anticarcinoma Antibody CC49,”Hybridoma14(5):461-473, 1995.
Kashmiri et al., “Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49,”Crit. Rev. Oncol. Hematol. 38:3-16, 2001.
Kashmiri et al., “SDR grafting—a new approach to antibody humanization,”Methods, 36:25-34, 2005.
Kashmiri et al., Chapter 21 inMethods in Molecular Biology, vol. 248:Antibody Engineering: Methods and Protocols, p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003.
Mulligan et al., “Phase I Study of Intravenous177Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma,”Clinical Cancer Research1:1447-1454, 1995.
Mullins et al., “Transgenesis in Nonmurine Species,”Hypertension, 22(4):630-633, Oct. 1993.
Mullins, et al., “Expressionof the DBA/2JRen-2 Gene in the Adrenal Gland of Transgenic Mice,”EMBO Journal, 8(13):4065-4072, Dec. 20, 1989.
Mullins, et al., “Fulminant Hypertension in Transgenic Rats Harbouring the MouseRen-2Gene,”Nature, 344:541-544, Apr. 5, 1990.
Mullins, et al., “Perspective Series: Molecular Medicine in Genetically Engineered Animals,”J Clin. Invest., 98(11):S37-S40, 1996.
Muraro et al., “Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen,”Cancer Research48:4588-4596, 1988.
Neimann, Prof. Dr. H., “Transgenic Farm Animals Get off the Ground,”Transgenic Research Journal, 7(1):73-75, Jan. 1998.
Overbeek, Paul A., “Factors Affecting Transgenic Animal Production,”Transgenic Animal Technology, pp. 96-98, 1994.
Padlan et al., “Identification of Specificity-determining Residues in Antibodies,”The FASEB Journal9:133-139, 1995.
Padlan, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties,”Molecular Immunology28(4/5):489-498, 1991.
Padlan, “Anatomy of the antibody molecule,”Mol. Immu
Kashmiri Syed V S
Padlan Eduardo A.
Schlom Jeffrey
Klarquist & Sparkman, LLP
Sang Hong
The United States of America as represented by the Secretary of
LandOfFree
Variants of humanized anti-carcinoma MAb CC49 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variants of humanized anti-carcinoma MAb CC49, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of humanized anti-carcinoma MAb CC49 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275819